30 Aug 2026

CRC Research Update — August 30, 2026

Creator: The CRC Digest
Published: 2026-08-30T11:27:20Z

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TRIAL DATA
COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC
The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology)
TRIAL DATA
Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC
The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology)
TRIAL DATA
Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer
The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology)
SCREENING
Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening
A rapid, label-free cell-free DNA assay measures global DNA hypomethylation—a hallmark of colorectal cancer—using electrical impedance to differentiate healthy individuals from those with cancer in a retrospective validation study. (Computational and Structural Biotechnology Journal)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

TREATMENT
Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC
A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not reach statistical significance. (The Lancet Oncology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

RESEARCH
Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified
A real-world next-generation sequencing study compared the genomic landscape of early-onset colorectal cancer with average-onset metastatic disease, identifying distinct molecular features in younger patients. (JCO Precision Oncology)

Research continues to advance our understanding of colorectal cancer across all stages and subtypes. As always, discuss any new findings with your care team to understand what they mean for your individual situation.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest